CIP
INSY

Convergence Investment Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

Convergence Investment Partners’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-44,905
Closed -$529K – 400
2016
Q3 		$529K Buy
44,905
+28,940
+181% +$440K 0.08% 282
2016
Q2 		$207K Sell
15,965
-104,286
-87% -$1.52M 0.03% 304
2016
Q1 		$1.92M Buy
+120,251
New +$2.28M 0.23% 154
2014
Q1 		– Sell
-52,350
Closed -$675K – 453
2013
Q4 		$675K Buy
+52,350
New +$726K 0.11% 224

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Convergence Investment Partners's INSY Position: Q4 2016 in Review

Convergence Investment Partners sold out of Insys Therapeutics, Inc. (INSY) in Q4 2016, closing a stake of 44,905 shares — an estimated $529K sold.

Convergence Investment Partners first reported a position in INSY in Q4 2013 and held it in 4 quarters. The position peaked at $1.92M in Q1 2016. 138 funds tracked by Wall St. Rank hold INSY as of Q4 2016.

  • Convergence Investment Partners reported no remaining Insys Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Convergence Investment Partners sold 44,905 Insys Therapeutics, Inc. shares in Q4 2016, an estimated $529K.
  • Convergence Investment Partners first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
  • Convergence Investment Partners's Insys Therapeutics, Inc. position peaked at $1.92M in Q1 2016.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2016.

Based on Convergence Investment Partners's 13F filing for Q4 2016, filed 13 Feb 2017.